Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's radiopharmaceutical sector, according to the European Medicines Agency (EMA). Vi ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

Following a turbulent period marked by Brexit and the pandemic, Ben Hargreaves finds the agency aiming to streamline processes and improve collaboration with applicants. The European Medicines ...

The European Medicines Agency's PRIME (PRIority MEdicines) initiative is a clear attempt to match the US FDA's Breakthrough Therapy Designation, which has been in place since 2012 and has ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

As we’ve been reporting, US Vice-President JD Vance says there is a “good chance” that the US and UK will come to a mutually ...

Follow the latest on Trump’s tariff war; Donald Trump has vowed to hit imports of pharmaceuticals with new tariffs in a major setback for one of Britain’s largest export indus ...

A federal court on Tuesday will hold a hearing on the case of a Maryland man wrongly deported to El Salvador, who Trump and the Salvadoran president made clear won’t be brought back to the US despite ...